Stoke Therapeutics (STOK) Other Non-Current Assets (2018 - 2026)
Stoke Therapeutics' (STOK) quarterly Other Non-Current Assets came in at $3.2 million in Q1 2026, up 347.57% year-on-year from $721000.0 in Q1 2025, and up 1321.59% quarter-over-quarter from $227000.0 in Q4 2025.
Stoke Therapeutics (STOK) Other Non-Current Assets (2018 - 2026) Analysis & Trends
Stoke Therapeutics' Other Non-Current Assets history runs 9 years deep, the most recent figure standing at $3.2 million for Q1 2026.
- On a quarterly basis, Other Non-Current Assets rose 347.57% year-over-year to $3.2 million in Q1 2026; TTM through Mar 2026 was $3.2 million, a 347.57% increase from a year earlier, with the FY2025 full-year figure at $227000.0, down 68.52% from the prior year.
- Other Non-Current Assets rose to $3.2 million in Q1 2026 per STOK's latest filing, from $227000.0 in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $3.2 million in Q1 2026 and bottomed at $227000.0 in Q4 2025.
- The 5-year median for Other Non-Current Assets is $569000.0 (2022), against an average of $732176.5.
- Across the five-year window, Other Non-Current Assets soared 881.03% in 2022 and sank 68.52% in 2025, its largest moves.
- Year by year, Other Non-Current Assets stood at $569000.0 in 2022, then changed by 0.0% to $569000.0 in 2023, then advanced by 26.71% to $721000.0 in 2024, then slumped by 68.52% to $227000.0 in 2025, then surged by 1321.59% to $3.2 million in 2026.
- Per Business Quant, the three latest STOK Other Non-Current Assets figures stand at $3.2 million (Q1 2026), $227000.0 (Q4 2025), and $721000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 1.02 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 104.24 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.26 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 2.13 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 124.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 14.48 Mn |
| 10 | Stoke Therapeutics | 1.87 Bn | 1.53 Bn | - | 3.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.23 Mn |
| Dec 31, 2025 | 227,000.00 |
| Sep 30, 2025 | 721,000.00 |
| Jun 30, 2025 | 721,000.00 |
| Mar 31, 2025 | 721,000.00 |
| Dec 31, 2024 | 721,000.00 |
| Sep 30, 2024 | 494,000.00 |
| Jun 30, 2024 | 494,000.00 |
| Mar 31, 2024 | 569,000.00 |
| Dec 31, 2023 | 569,000.00 |
| Sep 30, 2023 | 569,000.00 |
| Jun 30, 2023 | 569,000.00 |
| Mar 31, 2023 | 569,000.00 |
| Dec 31, 2022 | 569,000.00 |
| Sep 30, 2022 | 569,000.00 |
| Jun 30, 2022 | 569,000.00 |
| Mar 31, 2022 | 569,000.00 |
| Dec 31, 2021 | 569,000.00 |
| Sep 30, 2021 | 569,000.00 |
| Jun 30, 2021 | 75,000.00 |